James Kendrick, MD, FACOG

Board-Certified Gynecologic Oncologist

Focuses on all gynecologic cancers, including cervical, ovarian, uterine, vaginal and vulvar
Medical Director
James Kendrick, MD

James E. Kendrick, MD, FACOG is board certified in gynecologic oncology. He joined the Gynecologic Oncology Program at the Florida Hospital Cancer Institute in July of 2009. Dr. Kendrick graduated with honors from the University of Alabama School of Medicine. He then completed a four year residency in obstetrics and gynecology followed by a three year fellowship in gynecologic oncology at The University of Alabama at Birmingham. Dr. Kendrick is widely published in numerous academic journals, and currently serves as the principal investigator for all Gynecologic Oncology Group clinical trials available to our patients. His clinical interests include robotic surgery and the surgical and medical management of all gynecologic malignancies.


  • Clinical Trials
  • Gynecologic Oncology
  • Obstetrics and Gynecology
  • Ovarian and Other Gynecologic Cancers
  • Robotically Assisted Surgery


  • Detection of Sentinel Lymph Nodes in Patients with Endometrial Cancer Undergoing Robotic-Assisted Staging


  • Peri-operative Outcomes of Patients with Stage IV Endometriosis Undergoing Robotic-assisted Laparoscopic Surgery
  • Clinico-pathological and Surgical Outcomes Analyses of Cervical Cancer Patients Treated with Robotic-assisted Radical Hysterectomy

Points of Difference

  • Top 5 Nationally Gynecologic Robotic Programs
  • Affiliated with the National Cancer Institute’s Gynecologic Oncology Group (GOG)
  • Award-Winning Fellowship Program
  • Innovative Robotic Surgery Techniques
  • Internationally Recognized (clinical research, robotic surgery and treatment)
  • Nationally Ranked in Gynecology Oncology
  • Ongoing Research, Publications and Presentations
  • Quality Oncology Practice Initiative (QOPI) Certification
  • Ranked 10th in the Nation by U.S. News & World Report

Results & Outcomes

  • Clinical Trials
  • Access to Most Advanced Therapies Available
  • Advanced Stage Ovarian Cancer (higher than the national average)
  • Cervical Cancer (meets or exceeds the national average)
  • Stage IV Uterine Cancer (substantially higher than the national average)
  • Five-Year Survival Rates Report
  • Ongoing Research Projects
  • Ongoing Survival Data and Comparisons
(407) 966-4073